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INTRODUCTION
Two general problems are increasingly recognized and debated with regard to the improvements in cancer treatment: their small incremental size and the high price of the new drugs. The two problems are connected because modern clinical trials in advanced solid tumors have become larger and larger (with associated increasing costs), resulting in statistically significant findings being achieved with smaller and smaller observed treatment effects. This drug-development strategy has been based on a rationale, risk-minimizing philosophy by the pharmaceutical industry, however we suggest that we are approaching (or have already passed) an inflection point where continued pursuit of this strategy is not optimally productive.
Modest benefits could be considered worthwhile if associated with moderate costs and toxicity, whereas a new drug with a very high cost and/or substantial toxicity is worthwhile only if it produces sizeable clinical benefits. Hence, the relevance of statistical significance has increasingly been challenged when the treatment effect is small (1, 2) . The simple solution would be to raise the bar of efficacy for approving antineoplastic agents (3, 4) . As supporters of this concept (3), here we try to expand them by describing a structured approach to this problem in advanced solid tumors. We also apply our derived model to a large sample of the most important pivotal trials on biologic agents published during the last 15 years, to evaluate which of them would meet the criteria for success according to various threshold values of several efficacy parameters. 
METHODS
The definition of minimum CLINICALLY MEANINGFUL OUTCOME ( mCMO)
If a new treatment is to be introduced into clinical practice in the setting of 'superiority' to an existing treatment, it is not sufficient to demonstrate that it is 'better' than standard therapy. It
should be necessary to demonstrate that its benefits outweigh its adverse effects and costs. If the benefits are expressed in terms of OS, the increase in survival that balances the harms/costs of the treatment represents a threshold: the mCMO. This value should be considered as a cut-off between what is and what is not clinically meaningful. Until the treatment effect is shown with statistical rigor to be larger than this threshold, the treatment should still be considered experimental.
Factors affecting the mCMO
The extent of the benefit identifying mCMO may be a function of 3 factors: the prognosis of patients with that condition, the toxicity/inconveniences of the treatment and its cost. In addition , the extent of benefit may have different relevance according to the endpoint used (OS ,progression free survival (PFS) or others) and the way it is expressed (HR, absolute median gains etc). In general, depending on the prognosis and the setting of the disease, there is agreement that OS or PFS are the endpoints to be used in advanced solid cancers, with the first one being preferred whenever practical. Here we chose OS. Extending the approach to alternative endpoints, such as PFS, is feasible, but involves a substantial increase in the number and complexity of the issues to be addressed. For instance, in order to allow comparisons between the effects of different drugs and to provide estimates of benefit readily understandable by patients and health administrators it should be possible to translate effects on PFS into effects on OS, which is far from simple. For this reason we included in our analysis only those trials where OS mature data were reported.
Research. 
Structured approach to define the mCMO
We first focused on the identification of the best candidate parameters for the definition of the mCMO. Once those parameters were identified, we defined the threshold levels for each prognostic condition. We then arbitrarily set the bar of the mCMO at three different levels of required benefit (high, medium and low), assuming that it may be simple to adapt these thresholds to different toxicity and cost categories ( low, medium and high). For example, if a medium level of benefit is required, the threshold values could be maintained for a medium level of toxicity and cost, but these values could be raised to high if the toxicity or cost is high or lowered to low if toxicity or cost is low. In this way this model could grossly implement all 3 major determinants of benefit.
a. Parameters defining the thresholds of mCMO
Although HR is the parameter used in the design and interpretation of clinical trials, other summary statistical indices are also important. The median gain in OS is a straightforward figure that has the advantage of being easily understandable by patients and other stakeholders. The late effects of treatment have the same advantage, no matter whether expressed in terms of absolute increase in the survival rate at 2,3,5 years ( usually not so impressive, typically in the range of 5 to 15 %) or in terms of proportional increase in OS rates at 2,3,5 years ( usually more impressive figures, typically in the range of 20 to 50%). Therefore 4 OS-related parameters may contribute to define the mCMO (Figure 1 ): HR , gains in median OS , absolute and proportional gains in the long term survival rates, representing 2 conceptually different types of treatment effects: a small benefit for many (SMALL) and a large benefit for few (LARGE). SMALL may be measured both in terms of HR and gains in median OS, whereas LARGE may be more appropriately measured by proportional and or absolute increase in 2, 3 or 5-year OS. Three out of four parameters (median gain, absolute or proportional gain in OS rates) are in general easily understandable by patients. This would provide extra value by using a language that is appropriate for the patient-doctor relationship.
b. Raising the bar: the choice of threshold values for mCMO
We have considered two determinants for each of these 4 OS-related parameters: the extent of the required benefit and the prognosis of the condition under study.
-Extent of the required benefit. We have proposed 3 potential levels of the benefit representing the mCMO when a low, medium or high required benefit is the desired target ( Table 1 ). The "high" level might be used when the toxicity and/or the cost of the new drug are high, the "low" level may apply to drugs that are both non-toxic/safe and inexpensive, whereas the "medium" level could be used in intermediate cases.
The threshold values proposed for the "low" level are higher than many 'target' values used in current ongoing phase III trials, in keeping with the general concept of "raising the bar" in oncology.
-Prognosis of the condition under study. Because the mCMO also depends on the prognosis of the condition under study, we have identified 4 prognostic categories, based on the median OS observed with standard therapies: < 9 months , 9 to 12, 12 to 18 and > 18 months. These prognostic cut-off values were selected after a series of attempts to have a sizable and rather homogeneous number of trials in each prognostic category, but still reflecting the sense of poor, medium and good prognosis.
The threshold values for the 4 key parameters were arbitrarily selected using the following criteria:
-HR for OS: the maximum variation within each level of required benefit was set at 0.1. The HR variation within the same prognostic category was 0.05.
-Gains in Median OS: the minimum and maximum survival benefit was set at 2 and 6 months, respectively, as a function of the prognostic category, to reflect the perception that no benefit of Research.
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-Absolute gains in late OS: the 5 year OS values would have fully satisfied the concept of LARGE, but almost no trials report such late survival results in the advanced setting. Therefore we considered 2 or 3 years as late OS time points whenever the prognosis is below or above 12 months, respectively. Ranges between 2.5% and 20% were considered, and the range between 5% and 15 % was chosen because little difference was observed between 2.5% and 5% and the selection afforded by 15% was already very high.
-Proportional increase in 2 or 3 year OS: after testing various ranges, values between 25% and 100% were chosen because these values reflects concepts of benefit that may be easily conveyed to the patients and to non-medical stakeholders.
Field testing of the model : selection of the clinical trials
The postulated values defining mCMO for SMALL and LARGE were considered relative to the actual results of pivotal trials on new agents. These trials were selected according to the following criteria : 
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RESULTS
The consequences of raising the bar of the mCMO on the ranking of currently available drugs for advanced solid tumors: "SMALL".
Because it would be desirable to meet both criteria defining SMALL (HR for OS and gains in median OS) we have reported the number of trials that would meet both conditions (column "both" in Table 2 ). Only 2 trials reached the postulated "high" threshold values (Table 2A ). The number of "positive trials" increased to 8 and 15 when the bar was lowered to the "medium" and "low" levels, respectively (Table 2B and 2C). Table 2 also reports those trials meeting either criteria ( column "either" in Table 2 ). The corresponding figures for the 3 levels of required benefit were 8, 18 and 23 positive trials out of 43.
In addition, the table also reports which specific parameter each trial met (columns Hazard Ratio and Median gain in OS). In general meeting the postulated median gains was more common than achieving the HR thresholds. Table 3 reports which drug would pass the thresholds for the different required benefit levels. It may be noted that trastuzumab, clearly a paradigm-changing agent for breast cancer, exceeds only the 'medium' and 'low' required benefit level, based upon the pivotal registration trial data (12). This underlines how high the proposed "high" threshold levels are.
Research. The consequences of raising the bar of the mCMO on the ranking of currently available drugs for advanced solid tumors: "LARGE".
The same analysis as above was performed for LARGE, as measured by the absolute OS gains and or proportional OS increase at 2 or 3 years (Table 4 ).The analysis of these parameters was done at 2 years for conditions with poorer prognosis ( <12 months median survival with standard treatment) and at 3 years for conditions with better prognosis ( > 12 months) on trials reporting more than 20 patients at risk at these late times. Most trials lack this information: the number of qualifying trials was 18: eleven for the < 12 months groups , and 7 for the better prognosis groups. The table reveals that there are no trials satisfying both the absolute and proportional increase for the "high" required benefit levels (Table 4A , columns 'both'). Setting the bar at the "medium and low" threshold level (Table 4B and 4C, sum of the 2 columns 'both') allows 2 and 9 trials, respectively, to reach the postulated levels. If we consider the instances where trials satisfied the threshold of either endpoint (sum of the 2 columns 'either' in table 4 A, B and C), these numbers increase to 2, 8 and 11 for the high, medium and low levels, respectively.
DISCUSSION
The current trend of conducting ever larger trials looking for smaller and smaller benefits that are statistically significant, but clinically marginal, has been strongly criticized (2, 3, 4, 50) . We hope that the concepts proposed here set the stage for a new, more informed starting point for debate on these complex and controversial issues in three ways.
A) By specifically defining the new concept of the mCMO, the proposal goes beyond the vague concepts of "clinically worthwhile", "clinically relevant", "large deltas" etc. 
It should be clear that the approach we are suggesting does not represent an attempt to model the effect of treatments on the prognosis of cancer patients. In general, the treatment effects observed in a randomized clinical trial are compatible with a variety of statistical models, including those that assume a substantial heterogeneity in treatment effects across patients. For instance, a moderate increase in median OS may conceal a large effect in a small group of patients, with no effect in the remaining patients. What we propose here is simply an operational model that can prove useful to establish criteria for defining the clinical relevance of a new treatment.
It is quite obvious that patients and doctors would prefer pursuing LARGE rather than SMALL.
However, experience in clinical oncology suggests two key lessons in this regard: a) because cancer treatment advances are "incremental", their cumulative effects are missed if SMALL is rejected a priory; b), in some instances, the detection of LARGE benefits in molecularly defined subgroups of patients did not derive directly from preclinical or early clinical studies, but this recognition was initiated by the retrospective identification of these molecular parameters within studies demonstrating SMALL (see the entire anti EGFR story in advanced colorectal cancer).
Hence both types of the mCMO are relevant and should be pursued with the hope that LARGE will be pursued with increased frequency in molecularly defined populations.
This model suffers recognized limitations.
First and most important, there is no question that the future of oncology is to navigate towards a molecular classification of cancer. This will imply recognizing driving mutations that will hopefully be targetable by new drugs. Pursuing SMALL in these conditions is clearly inappropriate. However the SMALL philosophy, and consequently, conducting large trials on unselected patients populations, is still more prudent whenever no clear indications about the We believe that the basic principles (mCMO, SMALL and LARGE) as well as the structured approach presented here provide a critical refinement to the "raising the bar philosophy" recently emphasized. We also recognize that additional fine tuning, or more substantial adjustments to these concepts or threshold values by all stakeholders will improve the model further. Table 2 . mCMO for the high (A), medium (B) and low (C) required benefit for SMALL: number of trials meeting these criteria for success out of the 43 pivotal randomized studies analyzed according to the selection criteria described in the text. Table 4 . mCMO for the high (A), medium (B) and low (C) required benefit for "LARGE", measured by absolute OS increase (A column) and proportional OS increase (P column) at 2 years in poor prognosis groups (< 12 months) or at 3 years in good prognosis (>12 months) groups: number of trials meeting these criteria for success among the 18 trials ( of the 43 analyzed) reporting OS data on more than 20 patients at risk at the late term of 2 and 3 years.
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